Clinical trials: Scleroderma
Scleroderma, Systemic
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality.
- Trial name
- NCT02597933
- Testing
- Nintedanib
- Where
- 195 sites in United States, Argentina and 30 more
- Volunteers
- 580 people
- Sponsor
- Boehringer Ingelheim
Scleroderma, Digital Ulcers
Riociguat in Scleroderma Associated Digital Ulcers
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with…
- Trial name
- RESCUE (NCT02915835)
- Testing
- Riociguat
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dinesh Khanna, MD, MS
Scleroderma
Taking Charge of Systemic Sclerosis
This Study is a collaborative project with partners (people with scleroderma and stakeholders) designed to refine an internet program for patients with scleroderma and to compare the internet program to an authoritative…
- Trial name
- TOSS (NCT02494401)
- Testing
- Internet-based self-management program, Scleroderma book
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- University of Michigan
Scleroderma
Scleroderma ARFI Imaging of the Skin
Scleroderma and other rheumatologic conditions can affect the skin. Scleroderma in particular involves skin thickening and hardening.
- Trial name
- ARFI (NCT02006420)
- Testing
- ARFI-SVI Ultrasound
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Systemic Sclerosis-associated Interstitial Lung Disease
Abituzumab in SSc-ILD
The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the…
- Trial name
- NCT02745145
- Testing
- Abituzumab 1500 mg, Abituzumab 500 mg
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 24 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Systemic Sclerosis, Scleroderma
Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Systemic sclerosis is a chronic autoimmune connective tissue disorder with no universally accepted disease modifying regimen. Recruiting patients for systemic sclerosis treatment studies is difficult due to the limited…
- Trial name
- NCT01093885
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pennsylvania
Scleroderma
Hands on - a Hand Care Guide in Systemic Sclerosis
Hands are commonly affected in Systemic Sclerosis (SS). The objective of this research is to apply a home based hand care guide in patients with SS and to evaluate its response regarding hand pain, function, strength and mobility.
- Trial name
- NCT02610842
- Testing
- Handbook
- Where
- 2 sites in Brazil
- Volunteers
- 27 people
- Sponsor
- University of Campinas, Brazil
Morphea, Localized Scleroderma
Molecular Effects of Topical Calcipotriene on Morphea
This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea.
- Trial name
- NCT02411643
- Testing
- topical calcipotriene 0.005% ointment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Scleroderma, Systemic
Imatinib in Systemic Sclerosis
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs and widespread vasculopathy.
- Trial name
- NCT00506831
- Testing
- Imatinib mesylate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Systemic Scleroderma, Severe Systemic Sclerosis
Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis.
- Trial name
- NCT00622895
- Testing
- fludarabine phosphate, Mycophenolic Acid, tacrolimus
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Systemic Scleroderma, Pulmonary Hypertension
Placebo Controlled Trial of Bosentan in Scleroderma Patients
The purpose of this study is to determine whether the drug Bosentan improves exercise tolerance in scleroderma patients.
- Trial name
- NCT00377455
- Testing
- Bosentan
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Georgetown University
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Scleroderma, Systemic Sclerosis
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma,also known as systemic sclerosis (SSc), is a multisystem disease affecting skin and other tissues including joints, muscles, lungs, the gastrointestinal tract and kidneys and tissue fibrosis is widespread.
- Conditions
- Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
- Trial name
- NCT01538719
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston University
Systemic Sclerosis
Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
The purpose of this study is to assess the safety and tolerability of imatinib mesylate (Gleevec) in patients with systemic sclerosis (scleroderma).
- Trial name
- NCT00555581
- Testing
- Imatinib Mesylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hospital for Special Surgery, New York
Scleroderma, Diffuse, Scleroderma, Systemic
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Systemic sclerosis (scleroderma) is an autoimmune connective tissue disease that involves the skin and other internal organs for which there are few effective treatment options.
- Trial name
- NCT00442611
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Systemic Sclerosis
Nilotinib in the Treatment of Systemic Sclerosis
A phase IIa open-label single center pilot study to assess the safety and efficacy of Nilotinib in patients with Scleroderma.
- Trial name
- NCT01166139
- Testing
- Nilotinib (Tasigna)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hospital for Special Surgery, New York
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Scleroderma
High Dose Cyclophosphamide for Treatment of Scleroderma
Systemic Sclerosis (Scleroderma) varies greatly in clinical manifestations, mode of presentation, and course. The natural history of this chronic autoimmune disease ranges from benign to fatal.
- Trial name
- NCT00501995
- Testing
- IV Cyclophosphamide
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
n Ulcer, Scleroderma, Systemic
A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).
This is a research study of an investigational drug called ambrisentan (Letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.
- Trial name
- NCT00725361
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University